Evidence map›Paper›PMID 37039949›Full record

ArticleInternational journal of clinical oncology2023

The clinical impacts of postoperative complications after colon cancer surgery for the clinical course of adjuvant treatment and survival.

Toru Aoyama, Koji Oba, Michitaka Honda, Masaru Muto, Shuhei Mayanagi, Hiromichi Maeda, Mitsuro Kanda, Kosuke Kashiwabara, Junichi Sakamoto, Takaki Yoshikawa

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 1 country.

Toru AoyamaDepartment of Surgery, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan. t-aoyama@lilac.plala.or.jp.ORCID http://orcid.org/0000-0001-6803-3800
Koji ObaDepartment of Biostatistics, The University of Tokyo, Tokyo, Japan.
Michitaka HondaDepartment of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, Fukushima, Japan.
Masaru MutoJapanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, Japan.
Shuhei MayanagiDivision of Esophageal Surgery, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Hiromichi MaedaDepartment of Surgery, Kochi University, Kochi, Japan.
Mitsuro KandaDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kosuke KashiwabaraData Science Office, Clinical Research Promotion Center, The University of Tokyo Hospital, Tokyo, Japan.
Junichi SakamotoTokai Central Hospital, Gifu, Japan.
Takaki YoshikawaDepartment of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan.
Fukushima Medical University · JPJapanese Foundation for Multidisciplinary Treatment of Cancer · JPNagoya University · JPShizuoka Cancer Center · JPThe University of Tokyo · JPTokai Central Hospital · JPTokyo National Hospital · JPUniversity of Kochi · JPUniversity of Tokyo Hospital · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimWe investigated whether or not postoperative complications (POCs) themselves have a negative survival impact or indirectly worsen the survival due to insufficient adjuvant chemotherapy in a pooled analysis of two large phase III studies performed in Japan PATIENTS AND

methodsThe study examined the patients who enrolled in 1304, phase III study comparing the efficacy of 6 and 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer patients and in 882, a phase III study to confirm the tolerability of oxaliplatin, fluorouracil, and l-leucovorin in Japanese stage II/III colon cancer patients. In our study, POCs were defined as the following major surgical complications: anastomotic leakage, pneumonia, bowel obstruction/ileus, surgical site infection, postoperative bleeding, urinary tract infection, and fistula. Patients were classified as those with POCs (C group) and those without POCs (NC group).

resultsA total of 2095 patients were examined in the present study. POCs were observed in 169 patients (8.1%). The overall survival (OS) rates at 5 years after surgery were 75.3% in the C group and 86.5% in the NC group (p = 0.0017). The hazard ratio of POCs for the OS in multivariate analysis was 1.70 (95% confidence interval, 1.19 to 2.45; p = 0.0040). The time to adjuvant treatment failure (TTF) of adjuvant chemotherapy was similar between the groups, being 68.6% in the C group and 67.1% in the NC group for the 6-month continuation rate of adjuvant chemotherapy. The dose reduction rate of adjuvant chemotherapy and adjuvant treatment suspension rate were also similar between the groups (C vs. NC groups: 45.0% vs. 48.7%, p = 0.3520; and 52.7% vs. 55.0%, p = 0.5522, respectively).

conclusionPOCs were associated with a poor prognosis but did not affect the intensity of adjuvant chemotherapy. These results suggested that POCs themselves negatively influence the survival.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColonic NeoplasmsCapecitabineChemotherapy, AdjuvantDisease-Free SurvivalDisease ProgressionFluorouracilHumansLeucovorinNeoplasm StagingPostoperative ComplicationsCapecitabineFluorouracilLeucovorinAdjuvant treatmentColon cancerSurgical complicationSurvival

Identifiers

PMID37039949
PMCPMC10232630
OpenAlexW4364351736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.